NONALCOHOLIC STEATOHEPATITIS TREATMENT MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Nonalcoholic Steatohepatitis Treatment Market - Overview The Global Nonalcoholic Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1,119.8 million in 2017 (based on existing approved therapies including anti-diabetics, vitamins, dietary supplements, and others) and is projected to exhibit a CAGR of 42.7% over the forecast period (2018 - 2026). Nonalcoholic fatty liver disease (NAFLD) is a condition which occur due to the presence of fat in more than 5% of liver cells. NAFLD affects people who consume little or no alcohol. According to the Harvard Medical School, January 2018 report, NAFLD is the most common liver disease and affects nearly 25% of American adults, 60% of whom were men. It increases the risk of heart disease and if left untreated, it can lead to nonalcoholic steatohepatitis (NASH), a condition causing inflamed liver. More than 40% of people with NAFLD develop NASH which can lead to scarring of the liver. Severe liver scarring, known as cirrhosis, increases the risk of liver cancer. The most widely used treatment for NASH is to eliminate potential causes and risk factors such as weight loss and treatment for hyperglycemia or dyslipidemia. A study published by the National Center for Biotechnology Information in 2015, suggests that thiazolidinediones and vitamin E can help correct biochemical and histologic abnormalities in NASH. Browse Research Reports: https://www.coherentmarketinsights.com/marketinsight/nonalcoholic-steatohepatitis-treatment-market-2279 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Moreover, no medicines have been approved to treat NASH so far. However, researchers are developing medicines to improve the conditions. According to the National Institute of Diabetes and Digestive and Kidney Diseases, some studies suggest that pioglitazone (Actos), a medicine for type 2 diabetes, can improve NASH in people non-diabetic patients. Companies in the market are focusing on extensive research to develop medicine for NASH treatment. For instance, in 2017, Gilead Sciences, Inc. announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase, in patients with nonalcoholic steatohepatitis. Browse 26 Market Data Tables and 28 Figures spread through 187 Pages and indepth TOC on "Nonalcoholic Steatohepatitis Treatment Market, By Drug (Cenicriviroc, Elafibranor, Ocaliva, and Selonsertib), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026" Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2279 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Key Takeaways of the Nonalcoholic Steatohepatitis Treatment Market: The global nonalcoholic steatohepatitis treatment market is expected to expand at a CAGR of 42.7% during the forecast period (2018–2026), owing to increasing incidences of nonalcoholic fatty liver disease. According to the State of Obesity data, in 2016, approximately 100 million individuals in the U.S were suffering from have nonalcoholic fatty liver disease. Among region, Asia Pacific is expected to grow at highest rate owing to increasing population with diabetes owing to the rising prevalence of diabetes driven by a combination of factors including sedentary lifestyles, rapid urbanization, and unhealthy diets. According to the WHO, diabetes is a growing challenge in India with estimated 8.7% diabetic population in the age group of 20 and 70 years. Major players operating in the global nonalcoholic steatohepatitis treatment market include AstraZeneca Plc., Conatus Pharmaceuticals, Enzo Biochem, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Gilead Science, Immuron Ltd., Intercepts Pharmaceuticals, Novo Nordisk, Raptor Pharmaceutical Corporation, and Tobira Therapeutics, Inc. Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2279 Š Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
Š Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
Š Coherent market Insights. All Rights Reserved